期刊： LIVER TRANSPLANTATION, 2022; 28 (1)
This study verified whether radical treatment for hepatocellular carcinoma (HCC) oligo-recurrence after liver transplantation conveys survival benefit......
期刊： LIVER TRANSPLANTATION, 2022; 28 (6)
The effects of mammalian target of rapamycin (mTOR) inhibitors (sirolimus [SRL] and everolimus [EVL]) on survival in liver transplantation (LT) recipi......
期刊： LIVER TRANSPLANTATION, 2022; 28 (2)
The aim is to explore the impact of the Kasai procedure (KP) and the length of native liver survival time (NLST) on outcomes of liver transplantation ......
期刊： LIVER TRANSPLANTATION, 2020; 26 (8)
Liver transplantation (LT) is the only available curative treatment for patients with end-stage liver disease. Early allograft dysfunction (EAD) is a ......
期刊： LIVER TRANSPLANTATION, 2020; 26 (12)
Using grafts from extended criteria donors (ECDs) and donation after circulatory death (DCD) donors is a strategy to address organ shortage in liver t......
期刊： LIVER TRANSPLANTATION, 2020; 26 (11)
It has been shown that normothermic machine perfusion (NMP), a novel preservation method, is able to assess and resuscitate liver grafts with risk fac......
期刊： LIVER TRANSPLANTATION, 2020; 26 (6)
Small recurrent hepatocellular carcinoma (HCC) can show atypical imaging patterns, and a specific diagnostic algorithm for HCC is lacking. This study ......
期刊： LIVER TRANSPLANTATION, 2020; 26 (8)
Continuous renal replacement therapy (CRRT) is frequently used to treat recipients with renal failure before or after liver transplantation (LT), thou......
期刊： LIVER TRANSPLANTATION, 2020; 26 (1)
Biliary complications (strictures and leaks) represent major limitations in living donor liver transplantation. Mesenchymal stem cells (MSCs) are a pr......
期刊： LIVER TRANSPLANTATION, 2020; 26 (1)
Morbid obesity is considered a relative contraindication for liver transplantation (LT). We investigated if body mass index (BMI; lean versus obese) i......
